Glucose / Energy Metabolism
Fatty Acid Synthase Antibody
|
イイネ！(0)
| 
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #3189S | 100 μL | 46,000 | |
|
Fatty Acid Synthase抗体製品一覧
3189 の推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
3189:
-
Western Blotting
| 用途（希釈倍率） | |
| ウエスタンブロッティング(1:1,000) |
| 特異性・感度 | |
| 内在性レベルのFatty Acid Synthase タンパク質を検出します。 |
| 使用抗原 | |
| ヒトのFatty Acid Synthase タンパク質のAla1160 周辺由来の配列（合成ペプチド） |
Western Blotting
Western blot analysis of extracts from various cell lines, using Fatty Acid Synthase Antibody.
Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).Recently, increased expression of FASN has emerged as a phenotype common to most human carcinomas. In breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).
-
Katsurada, A. et al. (1990) Eur J Biochem 190, 427-33.
-
Wells, W.A. et al. (2006) Breast Cancer Res Treat 98, 231-40.
-
Kawamura, T. et al. (2005) Pathobiology 72, 233-240.
-
Shah, U.S. et al. (2006) Hum Pathol 37, 401-409.
-
Kuhajda, F.P. (2000) Nutrition 16, 202-8.
-
Tian, W.X. (2006) Curr Med Chem 13, 967-977.
-
Kusunoki, J. et al. (2006) Endocrine 29, 91-100.
PhosphoSitePlus®：
FASN